Ben Hickey
President Rayzebio
Seminars
Wednesday 22nd July 2026
Transforming Outcomes in Advanced SSTR-Positive Neuroendocrine Tumors: Phase 3 Progress with ^225Ac-DOTATATE Targeted Alpha Therapy
9:30 am
- Improving antitumor efficacy in β-PRRT–refractory NETs through high-LET-particle cytotoxicity
- Addressing dosimetry, radionuclide supply, and daughter isotope redistribution to optimize safety
- Expanding clinical accessibility via novel chelators, combination strategies, and optimized radiolabeling protocols
